Want to see VKTX full AI Analyst Report?
Top Page
Viking Therapeutics
(NASDAQ:VKTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$34.00
▼(-2.27% Downside)
Action:Reiterated
Date:07/30/26
The score reflects a balance between strong clinical/program momentum and reiterated runway into 2028 (supportive near-term), versus weak financial performance trends driven by accelerating losses and cash burn (dominant risk). Technicals add mild downside pressure with the stock trading below its 20-day average, while valuation is difficult to support with a negative P/E and no dividend.
Positive Factors
Phase III programs fully enrolled
Large, fully enrolled Phase III trials materially reduce execution and statistical risk versus early‑stage studies. Robust enrollment demonstrates operational capability, strengthens the regulatory dataset probability, and supports a clearer path to potential approval and commercialization over the next 2–3 years.
Negative Factors
Accelerating cash burn and widening losses
Sustained and accelerating cash outflows materially raise funding and dilution risk. Even with runway into 2028, persistent negative FCF and steep losses imply the company will likely need additional capital if timelines slip or spend remains elevated, pressuring shareholder dilution and strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase III programs fully enrolled
Large, fully enrolled Phase III trials materially reduce execution and statistical risk versus early‑stage studies. Robust enrollment demonstrates operational capability, strengthens the regulatory dataset probability, and supports a clearer path to potential approval and commercialization over the next 2–3 years.
Read all positive factors
Viking Therapeutics (VKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.00B
Dividend YieldN/A
Average Volume (3M)2.52M
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth-203.77%
CountryUS
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.66
Shares Outstanding116,652,940
10 Day Avg. Volume1,815,615
30 Day Avg. Volume2,521,002
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$92.08Price Target Upside164.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.75
Revenue Forecast (FY)N/A
Viking Therapeutics Business Overview & Revenue Model
Company Description
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administere...
How the Company Makes Money
null...
Viking Therapeutics Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 28, 2026
Earnings Call Sentiment Positive
The call highlights substantial clinical progress: fully enrolled large Phase III programs for subcutaneous VK2735, positive Phase II efficacy for both subcutaneous and oral formulations (notably up to 14.7% and 12.2% mean weight loss, respectively), initiation of an early-stage amylin/calcitonin program (VK3019), and organizational hires to support commercialization. These scientific and pipeline milestones are balanced against materially higher R&D spend, widening net losses and a meaningful cash decline (~28.9% year-to-date). Management reiterated cash runway into 2028 and expects cash burn to taper, while noting upcoming maintenance study data and oral Phase III initiation later in the year. Overall, clinical momentum and promising efficacy data are dominant positives, while financial burn and early-stage uncertainties are notable negatives.Positive Updates
Phase III VANQUISH Program Fully Enrolled and On Track
Both VANQUISH-1 (≈4,500 patients) and VANQUISH-2 (≈1,000 patients) are fully enrolled and progressing as planned; randomized arms include 7.5 mg, 12.5 mg, 17.5 mg and placebo with a 78-week primary endpoint assessing percent change in body weight.
Negative Updates
Sharp Increase in Research & Development Spending
R&D expense for Q2 2026 was $115.8 million vs $60.2 million in Q2 2025, an increase of approximately 92.4%; for the six months ended June 30, 2026 R&D was $266.0 million vs $101.5 million in 2025, an increase of ~162.1%, driven largely by clinical study activity and related costs.
Read all updates
Q2-2026 Updates
Positive
Negative
Phase III VANQUISH Program Fully Enrolled and On Track
Both VANQUISH-1 (≈4,500 patients) and VANQUISH-2 (≈1,000 patients) are fully enrolled and progressing as planned; randomized arms include 7.5 mg, 12.5 mg, 17.5 mg and placebo with a 78-week primary endpoint assessing percent change in body weight.
Read all positive updates
Company Guidance
The company reiterated near‑term development and financial timelines and metrics: Viking ended Q2 2026 with $502M in cash (down from $706M at 12/31/25) and expects runway into 2028; Q2 operating spending included R&D of $115.8M (vs. $60.2M Q2’25) and G&A of $16.9M (vs. $14.4M Q2’25), producing a Q2 net loss of $128.1M ($1.10/share) and a six‑month net loss of $286.3M ($2.47/share) with YTD R&D of $266M (vs. $101.5M YTD’25) and YTD G&A ~$30.8M (vs. $28.5M YTD’25); clinically, the VANQUISH Phase III subcutaneous program (randomized to 7.5, 12.5, 17.5 mg or placebo) remains on track (primary endpoint % change in body weight at 78 weeks) after rapid enrollment (~4,500 in VANQUISH‑1 by Nov 2025, ~1,000 in VANQUISH‑2 completed Q1’26), extensions expected late‑2026/early‑2027; oral VK2735 Phase III (two studies mirroring VANQUISH but ~75% smaller) is planned to start in Q4 2026; the maintenance range‑finding study (21‑week induction then a 12‑week maintenance window with weekly, every‑other‑week and monthly arms) was initiated Q4’25, is nearing completion with topline results expected later this quarter and an oral maintenance portion due H1 2027; Phase II toplines showed up to 14.7% (subQ) and 12.2% (oral) mean weight loss at 13 weeks (oral: up to 80% ≥10% vs 5% placebo), and a Phase I SAD for VK3019 (DACRA) is underway with further MAD/readouts expected into 2027.Viking Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -208.00K | -431.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -534.42M | -359.15M | -109.52M | -85.52M | -68.52M | -54.68M |
| Net Income | -534.80M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M |
Balance Sheet | ||||||
| Total Assets | 521.90M | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M |
| Cash, Cash Equivalents and Short-Term Investments | 501.66M | 705.74M | 902.61M | 362.08M | 155.49M | 202.10M |
| Total Debt | 4.09M | 137.00K | 1.12M | 1.26M | 1.56M | 29.00K |
| Total Liabilities | 113.58M | 76.67M | 28.04M | 20.07M | 23.21M | 8.78M |
| Stockholders Equity | 408.32M | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M |
Cash Flow | ||||||
| Free Cash Flow | -418.44M | -278.69M | -87.79M | -73.38M | -48.40M | -47.59M |
| Operating Cash Flow | -418.44M | -278.69M | -87.79M | -73.38M | -48.40M | -47.59M |
| Investing Cash Flow | 399.26M | 341.39M | -553.37M | -179.09M | 54.75M | 37.96M |
| Financing Cash Flow | 111.25M | 76.44M | 612.46M | 271.38M | 4.16M | 6.88M |
Viking Therapeutics Technical Analysis
Positive
34.79
Price Trends
34.27
Negative
33.44
Positive
33.78
Positive
Market Momentum
-0.69
Positive
47.92
Neutral
61.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VKTX, the sentiment is Positive. The current price of 34.79 is below the 20-day moving average (MA) of 35.14, above the 50-day MA of 34.27, and above the 200-day MA of 33.78, indicating a neutral trend. The MACD of -0.69 indicates Positive momentum. The RSI at 47.92 is Neutral, neither overbought nor oversold. The STOCH value of 61.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VKTX.
Viking Therapeutics Risk Analysis
Viking Therapeutics disclosed 76 risk factors in its most recent earnings report. Viking Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viking Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $8.25B | -14.15 | -69.59% | ― | ― | 1.28% | |
59 Neutral | $6.14B | -13.55 | -43.98% | ― | -100.00% | -33.88% | |
54 Neutral | $4.00B | -7.39 | -94.56% | ― | ― | -203.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $6.44B | -15.68 | -160.19% | ― | ― | -14.40% | |
51 Neutral | $3.34B | -12.83 | -38.33% | ― | -88.87% | -35.06% | |
47 Neutral | $2.55B | -4.59 | 392.35% | ― | 17.50% | -5.66% |
* Healthcare Sector Average
VKTX
Viking Therapeutics
34.44
-3.75
-9.82%
RARE
Ultragenyx Pharmaceutical
26.80
-0.59
-2.15%
XENE
Xenon
64.23
30.12
88.30%
SRRK
Scholar Rock Holding
51.89
20.43
64.94%
IMVT
Immunovant
39.89
25.13
170.26%
NAMS
NewAmsterdam Pharma Company
27.98
3.61
14.81%
Viking Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Viking Therapeutics Shareholders Back Board, Pay, and Auditor
Positive
May 26, 2026
On May 19, 2026, Viking Therapeutics held its 2026 Annual Meeting of Stockholders, with about 69.1% of eligible shares represented, and shareholders elected Class II directors J. Matthew Singleton and S. Kathryn Rouan to serve until the 2029 annua...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.